Standardized allergen extracts
Commercial- Indications
- Allergic rhinitis, Allergic asthma, Insect venom allergy
Company intelligence / Profile preview
Antigen Laboratories, Inc.
Missouri, United Statesfda.gov ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has conducted clinical trials for sublingual immunotherapy. One Phase 2 trial for cat hair (Felis domesticus) immunotherapy was completed, while another Phase 2 trial for short ragweed (Ambrosia artemisiifolia) immunotherapy was withdrawn[3].
- Therapeutic areas
- Immunology
- Modalities
- Allergenic extractsSublingual immunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Antigen Laboratories, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antigen Laboratories, Inc..